DaVita Inc. (DVA) fell 2.7% to $180.70 on November 3, 2026, days after a third-quarter report that beat estimates and nudged guidance higher. The stock is 6.5% below its October 29 peak, under its 40-week average, and sitting between its 50-day and 200-day averages. A proposed federal kidney care plan and a new legal probe weigh against a solid quarter. The balance of evidence leans negative, with medium conviction.
Why it matters
The quarter itself was good. Revenue reached $3.58 billion, up 4.6% from a year earlier, and adjusted earnings of $3.82 a share beat consensus by 6.9%, according to Yahoo! Finance. Management raised full-year adjusted EPS guidance to $14.30 to $15.20, and lifted its Integrated Kidney Care operating income target to at least $65 million, as Seeking Alpha reported. Yet the stock's closing peak of $193.31 came on October 29, the day of the report, and shares have given back 6.5% since. Good numbers did not hold the price up.
The reason is largely the regulatory overhang that predates earnings. On October 20, DaVita shares fell just over 6% after reports of an administration proposal, the Kidney Care National Plan, aimed at the concentrated structure of the dialysis market, according to Seeking Alpha. More competition and oversight would hit a business whose economics rest on that concentration. A law firm has since opened a securities fraud investigation into whether DaVita properly disclosed those risks, per Yahoo! Finance. An investigation is not a finding, but it keeps the issue in front of buyers.
Over the last five days the stock lost 0.5%, the S&P 500 (SPY) lost 2.1%, and the healthcare sector ETF (XLV) gained 2.8%. DaVita held up better than the market but trailed its sector by 3.4 points. Today's drop is a different matter: SPY rose 0.2% and XLV slipped 0.2%, while DVA fell 2.7% on volume about 56% below its 20-day average. Nothing in the news explains that move, and light volume suggests it reflects thin buying more than fresh selling.
The two sides are plain. The constructive case is the earnings beat, the raised guidance, and a consensus of buy among seven analysts with a mean price target of $222.29. The cautious case is that the policy proposal and the legal probe leave the multiple exposed, and the shares are trading below their 10-week and 40-week averages. At $180.70, the stock is 18.7% below the mean target, but the targets range from $165 to $287. The lowest sits below today's price, so the spread says analysts disagree widely on how much the regulatory risk is worth.
What the evidence says
On the long term, the thesis is weakened, not broken. The stock is up 59.1% year to date and 19.2% over six months, but it sits 25% below its 52-week high of $240.96 and below its 40-week average. That is a downtrend in the weekly picture. The shares are in a pullback phase, roughly 74% above the 52-week low of $103.87 but unable to reclaim the higher ground.
For the next two to six weeks, the balance of evidence leans negative, and conviction is medium: two of four checks point down. The daily trend runs with the weekly downtrend, and DVA has lagged XLV by 6.9% over 50 days while the sector has surged 10.9% in a month. The RSI is 50, so the stock is neither stretched nor oversold, and a decline has room to run without hitting an extreme.
The strongest case against that reading is relative strength. DVA leads the S&P 500 by 1.2% over 50 days, which is unusual for a stock in a weekly downtrend. Add a beat-and-raise quarter and a consensus buy rating, and there is a real argument that the October drop was an overreaction to policy headlines. That is why conviction stops at medium. It does not tip the balance, because the lead is over a market that itself has been weak, while the comparison with its own sector and the position below the 40-week average both say sellers still control the larger picture.
Levels that matter
The structure holds below $181.72, the 50-day average, where sellers have shown up on rallies. The price is $180.70, just under it. The trend would end above $191.39, a swing zone, on a weekly close. Beyond that sit $200 and $202.62. Below the price, support starts at the 200-day average at $177.79, then $175 and $171.24.
The breakout level is a daily close below $177.79. From there the math gives two targets: $171.24, which is 1.1 to 1, and $156.84, which is 3.5 to 1. The stop sits at $183.81, which is the 50-day average plus a quarter of the 14-day ATR of $8.38. The setup reaches the 3 to 1 threshold only through the second target. The first, closer target alone does not pay for the risk.
What would change the picture
A weekly close above $191.39 would be the first sign that buyers are back and the downtrend has ended. The non-price fact that would most likely drive it is clarity on the Kidney Care National Plan: a narrowed proposal, or evidence that it will not add meaningful competition or oversight for dialysis providers. The stock's own results are already good, so policy is what holds the multiple down.
What to watch
- Earnings: the third-quarter report came October 29, 2026, and the date of the next one is not in the data. The number that matters is the full-year adjusted EPS guidance, with a $14.75 midpoint, and whether it holds or rises.
- Sector and policy events: developments on the HHS kidney care plan and the securities investigation can move DVA before any company news. XLV's strength, up 10.9% in a month, makes DVA's lag more visible.
- Valuation: at $180.70 the stock is 18.7% below the $222.29 mean target, inside a $165 to $287 range. The gap shows how much of the regulatory risk analysts treat as temporary.